Video SiNON is dedicated to improving the lives of those who suffer from debilitating neurological diseases by increasing the ability of drugs to cross the Blood Brain Barrier (BBB). Our patented nanoparticle, the Carbon Dot, will enable pharmaceutical companies to encapsulate their drugs in a way which dramatically improves drug-localization to the brain. This allows for a reduction in overall dose administration to the patient, leading to reduced toxicity risk and side-effects while improving therapeutic index and cost-efficacy. Considering the rapid growth of the senior population, and subsequent increase in neurological disease, we believe that our novel technology is an essential part of the overall solution to this healthcare crisis in the US and around the world.

Video SiNON is dedicated to improving the lives of those who suffer from debilitating neurological diseases by increasing the ability of drugs to cross the Blood Brain Barrier (BBB). Our patented nanoparticle, the Carbon Dot, will enable pharmaceutical companies to encapsulate their drugs in a way which dramatically improves drug-localization to the brain. This allows for a reduction in overall dose administration to the patient, leading to reduced toxicity risk and side-effects while improving therapeutic index and cost-efficacy. Considering the rapid growth of the senior population, and subsequent increase in neurological disease, we believe that our novel technology is an essential part of the overall solution to this healthcare crisis in the US and around the world.

SiNON is dedicated to improving the lives of those who suffer from debilitating neurological diseases by increasing the ability of drugs to cross the Blood Brain Barrier (BBB). Our patented nanoparticle, the Carbon Dot, will enable pharmaceutical companies to encapsulate their drugs in a way which dramatically improves drug-localization to the brain. This allows for a reduction in overall dose administration to the patient, leading to reduced toxicity risk and side-effects while improving therapeutic index and cost-efficacy. Considering the rapid growth of the senior population, and subsequent increase in neurological disease, we believe that our novel technology is an essential part of the overall solution to this healthcare crisis in the US and around the world.